CAPR241220C17500
- 2.85
- -0.15-5.00%
Capricor Therapeutics Newsroom
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Capricor Therapeutics Analyst Ratings
Capricor Therapeutics Initiated With a Buy at JonesResearch
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $30
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Piper Sandler Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $35
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $77
Capricor Therapeutics: Strategic Positioning and Financial Stability Drive Buy Rating
Capricor Therapeutics Analyst Ratings
Piper Sandler Initiates Capricor Therapeutics(CAPR.US) With Buy Rating, Announces Target Price $35
Capricor Therapeutics Initiated With an Overweight at Piper Sandler
Buy Rating for Capricor Therapeutics: Promising Deramiocel Development and Strategic Partnerships
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Capricor Therapeutics (CAPR) Receives a Buy From Oppenheimer
Capricor Therapeutics Price Target Raised to $77.00/Share From $40.00 by HC Wainwright & Co.
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $77
Capricor Therapeutics Analyst Ratings
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
Buy Rating Affirmed for Capricor Therapeutics Amid Promising Developments in DMD-cardiomyopathy Treatment